With $24m @ 8/31/2024: Below has occurred since

With $24m @ 8/31/2024:

Below has occurred since then, starting Sept. 9th, 2024:

*As of today, the company has a new and improved relationship with the FDA – one that will remain a critical priority

*We believe the company has sufficient cash on hand to commence the contemplated clinical trials and push our development initiatives forward into 2025.

*relapsed/refractory micro-satellite stable colorectal cancer (“CRC”)....and expect to start screening patients in early 2025.

*pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months
___

*In addition to CRC, CytoDyn is investigating the role for leronlimab in two other oncology indications via strategic and low-cost research and development opportunities, and in collaboration with several reputable institutions.

*results from the preclinical Glioblastoma study in mice performed by the Albert Einstein College of Medicine should be released in the coming months.
___

*announced our selection of Syneos Health to serve as our clinical research organization (“CRO”) and implement our FDA-approved protocol to evaluate leronlimab in the treatment of patients with HIV and chronic inflammation

*and expect to start screening patients in December 2024.
___

*First, we are working on a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease.

*We are also grateful to the foundation that has tentatively agreed to fund this study
___

*CytoDyn will soon receive results from a preclinical study of leronlimab in a mouse model of MASH.
___

*CytoDyn will be partnering with the American Foundation for AIDS Research (amfAR) to sponsor the HIV LATCH
___
*FcRn pre-clinical trial @ no cost to Cytodyn.
___

*Shareholder GM 11/22/2024.
No new shares requested
___

$24m will easily cover our stated goals into 2025.

News on remaining protocols could come anytime.

Same with addtl publications.

They are managing the company, treasury & share structure, with precision that protects LL & shareholders, to a 1st cash infusion.

Infusion into a professionally structured & goals focused company.

Exactly what any level or type of partnership needs to see.

For the world to fully benefit from the safe science of LL/CCR5, on many disease indications.